Contains a total of 305 µg of antibodies and is a pre-mixed solution of 3 monoclonal antibodies against Complex II subunits 70 kDa Fp, 30 kDa Ip along with an antibody against Complex V alpha as a control. This cocktail can be used to verify isolated Complex II purity or to conveniently determine the levels of 2 of the 4 Complex II subunits in cell lines relative to the control protein (Complex V alpha).
Complex II is also called succinate ubiquinone oxidoreductase or more commonly succinate dehydrogenase complex. This complex is composed of four nuclear encoded subunits and contains a flavin (FAD), non-heme iron centers and a b-type cytochrome as prosthetic groups. It is both a component of the electron transport chain and an enzyme of the Krebs cycle. Complex II deficiencies are seen in OXPHOS genetic disease and found in a type of cancer called paraganglioma.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Use a concentration of 6 µg/ml. The antibody cocktail (1.5 mg/mL) should be diluted 250x to a final working concentration of 6 µg/mL for Western blotting.
Western blot - Complex II WB Antibody Cocktail (ab110410)
All lanes : Complex II WB Antibody Cocktail (ab110410) at 1/250 dilution
Lane 1 : human heart mitochondria at 10 µg Lane 2 : Immunoprecipitated Complex II at 0.5 µg
The Western blot cocktail ab110410 contains two Complex II subunits SDHA (70 kDa) and SDHB (30 kDa)and a general mitochondrial marker ATP synthase alpha subunit (F1α, 55 kDa). All three are present in the mitochondrial sample (1). The Complex II sample purified by Complex II immunoprecipitation beads (ab109799) shows only Complex II subunits (2).
This product has been referenced in:
Yan H et al. NR4A1-induced increase in the sensitivity of a human gastric cancer line to TNFa-mediated apoptosis is associated with the inhibition of JNK/Parkin-dependent mitophagy. Int J Oncol52:367-378 (2018).
Read more (PubMed: 29207128) »
Guerra F et al. Placing mitochondrial DNA mutations within the progression model of type I endometrial carcinoma. Hum Mol Genet20:2394-405 (2011).
Read more (PubMed: 21470976) »